DE69836740D1 - Amyloid beta protein (globularer aufbau und seine verwendung) - Google Patents

Amyloid beta protein (globularer aufbau und seine verwendung)

Info

Publication number
DE69836740D1
DE69836740D1 DE69836740T DE69836740T DE69836740D1 DE 69836740 D1 DE69836740 D1 DE 69836740D1 DE 69836740 T DE69836740 T DE 69836740T DE 69836740 T DE69836740 T DE 69836740T DE 69836740 D1 DE69836740 D1 DE 69836740D1
Authority
DE
Germany
Prior art keywords
addls
activity
formation
globular
amyloid beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69836740T
Other languages
English (en)
Other versions
DE69836740T2 (de
Inventor
A Krafft
L Klein
A Chromy
P Lambert
E Finch
Todd Morgan
Pat Wals
Irina Rozovsky
Ann Barlow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northwestern University
University of Southern California USC
Original Assignee
Northwestern University
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwestern University, University of Southern California USC filed Critical Northwestern University
Application granted granted Critical
Publication of DE69836740D1 publication Critical patent/DE69836740D1/de
Publication of DE69836740T2 publication Critical patent/DE69836740T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE69836740T 1997-02-05 1998-02-05 Amyloid beta protein (globulärer aufbau und seine verwendung) Expired - Lifetime DE69836740T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US796089 1997-02-05
US08/796,089 US6218506B1 (en) 1997-02-05 1997-02-05 Amyloid β protein (globular assembly and uses thereof)
PCT/US1998/002426 WO1998033815A1 (en) 1997-02-05 1998-02-05 Amyloid beta protein (globular assembly and uses thereof)

Publications (2)

Publication Number Publication Date
DE69836740D1 true DE69836740D1 (de) 2007-02-08
DE69836740T2 DE69836740T2 (de) 2007-10-11

Family

ID=25167266

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69836740T Expired - Lifetime DE69836740T2 (de) 1997-02-05 1998-02-05 Amyloid beta protein (globulärer aufbau und seine verwendung)

Country Status (12)

Country Link
US (2) US6218506B1 (de)
EP (2) EP1808444A1 (de)
JP (2) JP3512815B2 (de)
AT (1) ATE349467T1 (de)
AU (1) AU735825B2 (de)
BR (1) BR9807185A (de)
CA (1) CA2279555C (de)
DE (1) DE69836740T2 (de)
DK (1) DK0998495T3 (de)
ES (1) ES2280090T3 (de)
PT (1) PT998495E (de)
WO (1) WO1998033815A1 (de)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068316A1 (en) * 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US20060178302A1 (en) * 1997-02-05 2006-08-10 Northwestern University & The University Of Southern California Amyloid beta protein (globular assembly and uses thereof)
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
WO2000075324A2 (en) 1999-06-09 2000-12-14 Arch Development Corporation Recombinant prion-like genes and proteins and materials and methods comprising same
DE60016227T2 (de) 1999-08-04 2005-12-15 Northwestern University, Evanston Globularer aufbau vom amyloid-beta- protein und deren verwendungen
PE20010978A1 (es) 1999-12-23 2001-09-14 Upjohn Co ENSAYOS Y METODOS DE DIAGNOSTICO QUE INVOLUCRAN CANALES DE SODIO COMO OBJETIVOS DE AMILOIDE ß O DE SUS AGREGADOS
CN1426423B (zh) * 2000-02-24 2010-05-12 华盛顿大学 螯合淀粉样蛋白β肽的人源化抗体
EP1309341A2 (de) * 2000-07-07 2003-05-14 Lars Lannfelt Prävention und behandlung der alzheimer krankheit
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US6815175B2 (en) * 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
DK1944040T3 (da) * 2001-08-17 2012-10-29 Univ Washington Analysefremgangsmåde for Alzheimers sygdom
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
AU2003279728B2 (en) * 2002-10-01 2007-09-27 Northwestern University Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
ZA200505782B (en) * 2003-02-01 2006-09-27 Neuralab Ltd Active immunization to generate antibodies to soluble A-beta
US7575747B2 (en) * 2003-02-10 2009-08-18 Applied Molecular Evolution Aβ binding molecules
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US8250823B2 (en) 2003-08-26 2012-08-28 Ejot Gmbh & Co. Kg Dowels and methods for the assembly of insulating panels
EP1755644A2 (de) * 2004-05-14 2007-02-28 Northwestern University Zubereitung enthaltend addlrezeptor syngap
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
WO2006047254A1 (en) * 2004-10-22 2006-05-04 Regents Of The University Of Minnesota Assemblies of oligomeric amyloid beta protein and uses thereof
NZ554725A (en) 2004-10-25 2009-10-30 Merck & Co Inc Anti-ADDL antibodies and uses thereof
PE20061329A1 (es) * 2004-12-15 2006-12-08 Neuralab Ltd Anticuerpos ab humanizados para mejorar la cognicion
TW200635608A (en) * 2004-12-15 2006-10-16 Neuralab Ltd Aβ antibodies for use in improving cognition
PE20061152A1 (es) * 2004-12-15 2006-10-13 Neuralab Ltd Anticuerpos humanizados que reconocen el peptido beta amiloideo
US7731962B2 (en) * 2005-02-14 2010-06-08 Merck & Co., Inc. Anti-ADDL monoclonal antibody and use thereof
US8420093B2 (en) 2005-02-14 2013-04-16 Merck Sharp & Dohme Corp. Anti-ADDL monoclonal antibody and use thereof
NZ560689A (en) * 2005-03-05 2010-12-24 Abbott Gmbh & Co Kg Screening method, process for purifying of non-diffusible abeta oligomer, selective antibodies against said non-diffusible abeta oligomers and a process for manufacturing of said antibodies
AU2006222193B2 (en) * 2005-03-05 2011-11-17 AbbVie Deutschland GmbH & Co. KG Screening method, process for purifying of non-diffusible A-beta oligomers, selective antibodies against said non-diffusible A-beta oligomers and a process for manufacturing of said antibodies
DE102005014936A1 (de) 2005-03-24 2006-12-14 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
WO2007016357A1 (en) * 2005-07-29 2007-02-08 Regents Of The University Of Minnesota Amyloid beta receptor and uses thereof
US20080014596A1 (en) * 2005-11-16 2008-01-17 Jasna Jerecic ADDL Binding to Hippocampal Neurons
EP2289909B1 (de) 2005-11-30 2014-10-29 AbbVie Inc. Screeningsverfahren, Verfahren zur Reinigung von nicht-diffundierenden Beta-Oligomeren, selektive Antikörper gegen genannten nichtdiffundierende Beta-Oligomere und Verfahren zur Herstellung von genannten Antikörpern
CN102898519B (zh) * 2005-11-30 2015-10-28 Abbvie公司 抗淀粉样β蛋白的单克隆抗体及其用途
EP1963363A2 (de) 2005-11-30 2008-09-03 Abbott Laboratories Verfahren zur herstellung rekombinanter formen von humanem beta-amyloid-protein und verwendung dieser proteine
EP1959996A2 (de) 2005-12-12 2008-08-27 AC Immune S.A. Monoklonaler antikörper
MY169492A (en) 2006-03-23 2019-04-15 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
JP4876224B2 (ja) * 2006-06-05 2012-02-15 財団法人ヒューマンサイエンス振興財団 アミロイドβオリゴマー並びにその製造方法及び使用方法
EP2046833B9 (de) * 2006-07-14 2014-02-19 AC Immune S.A. Humanisierter antikörper gegen amyloid beta
ES2323725T3 (es) * 2006-07-28 2009-07-23 Vista Ventures Gmbh Procedimiento para la deteccion de oligomeros de amiloide beta en fluidos corporales.
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2842967B1 (de) * 2007-01-18 2016-11-30 Eli Lilly and Company Pegyliertes Amyloid-beta-Fab
EP2124952A2 (de) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Verfahren zur behandlung von amyloidosen
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
MX2009011127A (es) * 2007-04-18 2010-03-10 Janssen Alzheimer Immunotherap Metodo de prevencion y tratamiento de angiopatia amiloide cerebral.
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
CL2008001741A1 (es) * 2007-06-12 2008-11-21 Genentech Inc Anticuerpo quimerico o humanizado o fragmento de los mismos que se unen especificamente a por lo menos un epitope en la proteina beta-amiloide; molecula de acido nucleico que lo codifica; composicion que lo comprende; y su uso para tratar enfermedades asociados con la formacion de placas amiloides.
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US20110098309A1 (en) * 2007-07-12 2011-04-28 Acumen Pharmaceuticals, Inc. Methods of inhibiting the formation of amyloid-beta diffusable ligands using acylhydrazide compounds
US9006283B2 (en) * 2007-07-12 2015-04-14 Acumen Pharmaceuticals, Inc. Methods of modifying amyloid β oligomers using non-peptidic compounds
WO2009008890A1 (en) 2007-07-12 2009-01-15 Acumen Pharmaceuticals, Inc. METHODS OF MODIFYING AMYLOID β OLIGOMERS USING NON-PEPTIDIC COMPOUNDS
US8962677B2 (en) * 2007-07-12 2015-02-24 Acumen Pharmaceuticals, Inc. Methods of restoring cognitive ability using non-peptidic compounds
SI2182983T1 (sl) 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
SG178809A1 (en) * 2007-10-05 2012-03-29 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
PL2238166T3 (pl) * 2007-10-05 2014-07-31 Genentech Inc Zastosowanie przeciwciała anty-Beta amyloidowego w chorobach oczu
US8932558B2 (en) * 2007-10-05 2015-01-13 Plaxgen Inc Multi-subunit biological complexes for treatment of plaque-associated diseases
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US20100291071A1 (en) * 2008-08-01 2010-11-18 Immunas Pharma, Inc. Antibody Specific Binding to A-Beta Oligomer and the Use
CN101965365A (zh) * 2007-10-19 2011-02-02 伊缪纳斯制药株式会社 能够特异性结合Aβ寡聚体的抗体及其应用
US8993714B2 (en) * 2007-10-26 2015-03-31 Imiplex Llc Streptavidin macromolecular adaptor and complexes thereof
US9217024B2 (en) 2007-12-18 2015-12-22 Acumen Pharmaceuticals, Inc. ADDL receptor polypeptides, polynucleotides and host cells for recombinant production
CN102936287B (zh) * 2008-02-08 2015-09-09 伊缪纳斯制药株式会社 能够特异性结合Aβ寡聚体的抗体及其应用
US9085614B2 (en) 2008-08-01 2015-07-21 Immunas Pharma, Inc. Antibodies that specifically bind to Aβ oligomers and uses thereof
US9102526B2 (en) 2008-08-12 2015-08-11 Imiplex Llc Node polypeptides for nanostructure assembly
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
ES2641612T3 (es) 2009-04-17 2017-11-10 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a oligómeros de beta A y uso de los mismos
WO2010132363A1 (en) 2009-05-11 2010-11-18 Imiplex Llc Method of protein nanostructure fabrication
EP2462161B1 (de) 2009-08-06 2017-03-08 Immunas Pharma, Inc. Spezifisch an abeta-oligmomere bindende antikörper und ihre verwendung
WO2011016239A1 (en) 2009-08-06 2011-02-10 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
EP2463369A4 (de) 2009-08-07 2013-09-18 Kyowa Hakko Kirin Co Ltd Humanisierter antikörper gegen amyloid-b-oligomere
JP5051806B2 (ja) 2009-08-07 2012-10-17 協和発酵キリン株式会社 抗アミロイドβオリゴマーヒト化抗体
EP2368558A1 (de) 2010-03-23 2011-09-28 Mdc Max-Delbrück-Centrum Für Molekulare Medizin Berlin - Buch Azoverbindungen zur Reduzierung der Bildung und der Toxizität von Amyloid-Beta-Aggregationszwischenprodukten
CN102933601B (zh) 2010-04-15 2016-06-08 Abbvie公司 β淀粉样蛋白结合蛋白
DK2593475T3 (en) 2010-07-14 2016-05-30 Merck Sharp & Dohme Anti-ADDL monoclonal antibody and uses thereof
US9176151B2 (en) 2010-07-14 2015-11-03 Acumen Pharmaceuticals, Inc. Antibodies, kit and method for detecting amyloid beta oligomers
MX341369B (es) 2010-07-30 2016-08-17 Genentech Inc * Anticuerpo anti-beta-amiloide humanizado seguro y funcional.
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
RU2014105172A (ru) 2011-07-13 2015-08-20 Мерк Шарп И Доум Корп. Способ обнаружения олигомеров бета-амилоида в образце жидкости организма и варианты его применения
US9377472B2 (en) 2012-04-30 2016-06-28 Amoneta Diagnostics Biological complex specific for Alzheimer's disease detection in vitro and use thereof
DK3099296T3 (en) 2014-01-31 2019-04-15 Cognition Therapeutics Inc ISO-INDOLINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE
MA40224B1 (fr) 2014-07-10 2021-05-31 Eisai R&D Man Co Ltd Anticorps se liant aux protofibrilles ass améliorés

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2203620T3 (es) 1992-10-26 2004-04-16 Elan Pharmaceuticals, Inc. Procedimientos para la identificacion de los inhibidores de la produccion del peptido beta-amiloide.
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)

Also Published As

Publication number Publication date
JP2004091492A (ja) 2004-03-25
JP2001501972A (ja) 2001-02-13
US6218506B1 (en) 2001-04-17
CA2279555A1 (en) 1998-08-06
ES2280090T3 (es) 2007-09-01
BR9807185A (pt) 2000-01-25
ATE349467T1 (de) 2007-01-15
US20060166275A1 (en) 2006-07-27
DK0998495T3 (da) 2007-05-07
DE69836740T2 (de) 2007-10-11
EP0998495A1 (de) 2000-05-10
PT998495E (pt) 2007-03-30
AU735825B2 (en) 2001-07-19
CA2279555C (en) 2012-05-01
AU6273598A (en) 1998-08-25
WO1998033815A1 (en) 1998-08-06
EP1808444A1 (de) 2007-07-18
JP3512815B2 (ja) 2004-03-31
EP0998495B1 (de) 2006-12-27
US7638283B2 (en) 2009-12-29

Similar Documents

Publication Publication Date Title
DE69836740D1 (de) Amyloid beta protein (globularer aufbau und seine verwendung)
DE60016227D1 (de) Globularer aufbau vom amyloid-beta- protein und deren verwendungen
DE69635740D1 (de) Diagnose und behandlung von mit aur-1 und/oder aur-2 assoziierten erkrankungen
DE69841653D1 (de) Katalytische monoklonale antikörper mit proteaseaktivität zur selektiven lysis der proteinkomponente von mit pathologischen konditionen zusammenhängenden plaques und aggregaten
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
ATE485303T1 (de) Isoformen von gehirn-natriuretischem peptid
NO976094L (no) Nye peptider avledet av humant varmesjokkprotein 60 for behandling av diabetes, fremgangsmåte og sett
DE69840752D1 (de) Verwendung von coumarine zur behandlung von lebererkrankungen und pankreaserkrankungen
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
WO1999033870A3 (en) Human regulatory proteins
DE59806627D1 (de) Arylsulfonamide und analoga und ihre verwendung zur behandlung von neurodegenerativen erkrankungen
ATE499445T1 (de) Menschliche ubiqutin ligase e3. verwendung für die modulation von nf-kappa b
DE68909465T2 (de) Behandlung von Pferdeviehbestand.
DE69729735D1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE69837148D1 (de) Chimäre proteine zur behandlung von diabetes
DE69910425D1 (de) Neue therapeutische verwendung von nicergoline
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.
DE69809223T2 (de) 5-alpha-pregnan-3-beta-ol-20-one 3-sulfate für di behandlung von tumoren und zns krankheiten
DE69408394D1 (de) 4-Piperidino-piperidin zur Behandlung von Tumoren
DE69734890D1 (de) Rdgb-proteine
DE68908445D1 (de) Mittel zur behandlung von lebererkrankungen.
ATE247467T1 (de) Neue therapeutische verwendung von 1,6-dimethyl- 8beta-hydroxymethyl-10alpha-methoxyergolin
DE58903550D1 (de) Mittel zur behandlung von chronisch entzuendlichen darmerkrankungen.
DE69714424D1 (de) Verwendung von kolostrum zur behandlung von darmverstopfung
WO2001066745A3 (en) Presenilin/crk binding polypeptides (pcbp) and methods of use thereof

Legal Events

Date Code Title Description
8364 No opposition during term of opposition